Randomised, double-blind, placebo-controlled efficacy and safety study of IGF-I trophic factor in Friedreich's Ataxia. [ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TROFICO IGF-I EN LA ATAXIA DE FRIEDREICH]

Trial Profile

Randomised, double-blind, placebo-controlled efficacy and safety study of IGF-I trophic factor in Friedreich's Ataxia. [ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TROFICO IGF-I EN LA ATAXIA DE FRIEDREICH]

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2012

At a glance

  • Drugs Mecasermin (Primary)
  • Indications Friedreich's ataxia
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top